EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Consistency of Serial Cerebrospinal Fluid α‐Synuclein Seed Amplification Assay Results in the Parkinson's Precision Medicine Initiative

David G Coughlin iD, Caroline Gochanour iD, Jie Yin iD, Luis Concha-Marambio iD, Carly Farris, Yihua Ma, David-Erick Lafontant iD, Edwin Jabbari iD, Tanya Simuni iD, Ken Marek, Thomas F Tropea, Parkinson's Precision Medicine Initiative

Movement Disorders · 12.10.2026

DOI: 10.1002/mds.70509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 12.10.2026. Verfasst von David G Coughlin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California, San Diego, La Jolla, California, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Michael J. Fox Foundation for Parkinson's Research, Medical Research Council Clinician Scientist Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies reporting α‐synuclein seed amplification assay (aSyn‐SAA) results are often cross‐sectional.

Objectives

In this study, we investigated the intraindividual consistency of aSyn‐SAA results (Amprion) over time from participants in the Parkinson's Precision Medicine Initiative (PPMI).

Methods

A total of 1238 participants had >1 cerebrospinal fluid (CSF) aSyn‐SAA result for analysis (Parkinson's disease [PD] = 633, prodromal = 563, healthy control [HC] = 42), collected over a median (minimum, maximum) of 2.0 (0.4, 11.4) years. Emphasis was placed on evaluating consistency in aSyn‐SAA‐PD participants, aSyn‐SAA + HC participants, and conversion rates from aSyn‐SAA negative to positive results prodromal participants.

Results

Of aSyn‐SAA + PD participants, 96% (474/493, 95% confidence interval [CI]: 94%–98%) remained positive in subsequent samples, and 92% (116/126, 95% CI: 86%–96%) of aSyn‐SAA‐PD participants remained negative. Ninety‐nine percent (303/307, 95% CI: 97%–99%) of aSyn‐SAA + prodromal participants remained positive, and 95% (234/247, 95% CI: 91%–97%) of aSyn‐SAA‐prodromal participants remained negative. Eighty‐nine percent (16/18, 95% CI: 67%–97%) of aSyn‐SAA + HC participants remained positive, and 87% (20/23, 95% CI: 68%–95%) of aSyn‐SAA‐HC participants remained negative. Conclusions aSyn‐SAA testing is highly consistent over time, even in less expected scenarios. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

Stichwörter der Autor:innen

CSFParkinson's diseasealpha‐synuclein seed amplification assay

Autor:innen und Institutionen

  • Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.
  • Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
  • Research and Development Department, Amprion, San Diego, California, USA.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Department of Neurology, Northwestern University, Chicago, Illinois, USA.
  • Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.

ORCID-Profile: David G Coughlin, Caroline Gochanour, Jie Yin, Luis Concha-Marambio, David-Erick Lafontant, Edwin Jabbari, Tanya Simuni

Förderung

  • NINDS NIH HHS
  • Michael J. Fox Foundation for Parkinson's Research
  • Medical Research Council Clinician Scientist Fellowship
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Coughlin, D. G., Gochanour, C., Yin, J., Concha-Marambio, L., Farris, C., Ma, Y., Lafontant, D. E., Jabbari, E., Simuni, T., Marek, K., Tropea, T. F., & Parkinson's Precision Medicine Initiative (2026). Consistency of Serial Cerebrospinal Fluid α‐Synuclein Seed Amplification Assay Results in the Parkinson's Precision Medicine Initiative. Movement Disorders. https://doi.org/10.1002/mds.70509

Vancouver

Coughlin DG, Gochanour C, Yin J, Concha-Marambio L, Farris C, Ma Y, et al. Consistency of Serial Cerebrospinal Fluid α‐Synuclein Seed Amplification Assay Results in the Parkinson's Precision Medicine Initiative. Movement Disorders. 2026. doi:10.1002/mds.70509

BibTeX
@article{Coughlin2026,
  author = {Coughlin, David G and Gochanour, Caroline and Yin, Jie and Concha-Marambio, Luis and Farris, Carly and Ma, Yihua and Lafontant, David-Erick and Jabbari, Edwin and Simuni, Tanya and Marek, Ken and Tropea, Thomas F and Parkinson's Precision Medicine Initiative, Parkinson's Precision Medicine Initiative},
  title = {Consistency of Serial Cerebrospinal Fluid α‐Synuclein Seed Amplification Assay Results in the Parkinson's Precision Medicine Initiative},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70509}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche